| pubmed-article:109703 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:109703 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:109703 | lifeskim:mentions | umls-concept:C0278601 | lld:lifeskim |
| pubmed-article:109703 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:109703 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:109703 | pubmed:dateCreated | 1979-8-29 | lld:pubmed |
| pubmed-article:109703 | pubmed:abstractText | Thirty-two patients with a diagnosis of primary inflammatory breast carcinoma were treated with combination chemoimmunotherapy consisting of 5-fluorouracil, doxorubicin hydrochloride (Adriamycin), and cyclophosphamide (FAC) plus BCG followed by radiation therapy. This group of patients was compared to a group of 32 consecutive historical controls treated with radiation therapy alone. The estimated mean disease-free interval for the FAC-BCG group was 16 months, compared to 9 months for the radiation therapy alone group (P less than 0.01). The estimated median survival for the FAC-BCG treated group was 24 months, compared to 18 months for the radiation therapy alone group (P = less than 0.03). The combined modality approach consisting of chemoimmunotherapy and radiation therapy significantly improved the disease-free interval and survival of patients with inflammatory breast carcinoma. | lld:pubmed |
| pubmed-article:109703 | pubmed:language | eng | lld:pubmed |
| pubmed-article:109703 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:109703 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:109703 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:109703 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:109703 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:109703 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:109703 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:109703 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:109703 | pubmed:issn | 0022-4790 | lld:pubmed |
| pubmed-article:109703 | pubmed:author | pubmed-author:HershE MEM | lld:pubmed |
| pubmed-article:109703 | pubmed:author | pubmed-author:GuttermanJ... | lld:pubmed |
| pubmed-article:109703 | pubmed:author | pubmed-author:BlumenscheinG... | lld:pubmed |
| pubmed-article:109703 | pubmed:author | pubmed-author:TashimaC KCK | lld:pubmed |
| pubmed-article:109703 | pubmed:author | pubmed-author:KrutchikA NAN | lld:pubmed |
| pubmed-article:109703 | pubmed:author | pubmed-author:HortobagyiG... | lld:pubmed |
| pubmed-article:109703 | pubmed:author | pubmed-author:BuzdarA UAU | lld:pubmed |
| pubmed-article:109703 | pubmed:author | pubmed-author:YapH YHY | lld:pubmed |
| pubmed-article:109703 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:109703 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:109703 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:109703 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:109703 | pubmed:pagination | 325-32 | lld:pubmed |
| pubmed-article:109703 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-H... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-B... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-A... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-F... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-A... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-B... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-A... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-M... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-T... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-D... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-R... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-C... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-F... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-R... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-R... | lld:pubmed |
| pubmed-article:109703 | pubmed:meshHeading | pubmed-meshheading:109703-D... | lld:pubmed |
| pubmed-article:109703 | pubmed:year | 1979 | lld:pubmed |
| pubmed-article:109703 | pubmed:articleTitle | Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. | lld:pubmed |
| pubmed-article:109703 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:109703 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:109703 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:109703 | lld:pubmed |
